News

EMA has insisted that the concerns raised about its scientific advice given to pharmaceutical companies stem from a flawed understanding of the activities of the agency and its partners in this area.

A potential treatment for sickle cell disease has come through early stage development due to support from a collaborative partnership established by NCATS at the NIH.

WIRB-Copernicus Group announced that it has acquired Alliance Biosciences.

Dr. Paul Wicks, head of innovation at PatientsLikeMe, detailed for Applied Clinical Trials, the three services the company announced at DIA.

Bracket announced that Biotie Therapies has selected its CDR System for use as the primary endpoint for their Phase II trial.

Two experts have engaged in a lively debate about whether research fraud should be classed as a criminal act.

Chiltern and Ockham announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations.

Chiltern and Ockham today announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations.

Industry news focusing on the people and organizations who work in the clinical trials profession.

This guidance document is being distributed for comment purposes only.

The Clinical Conductor CTMS team is proud to announce yet another major advancement in CTMS technology.

Theorem Clinical Research and Excel Life Sciences (ELS) have formed a strategic relationship

Theorem Clinical Research and Excel Life Sciences have formed a strategic relationship.

Bio-Optronics' Clinical Conductor CTMS team announced new features in the latest release of Clinical Conductor

Funds to Accelerate iMedNet EDC Sales, Marketing and R&D Initiatives

Why the requirement for the collection of cardiac safety data?

The European Confederation of Pharmaceutical Entrepreneurs is very concerned about legislative developments on the use of off-label medicines in France.

The Lithuanian Ministry of Health and EFPIA have announced a new Joint Working Agreement.

Although the pace of approvals for new orphan drugs have increased in the United States and Europe in recent years, patients are facing growing challenges accessing those drugs.

Recruiting patients remains one of the most difficult challenges clinical trial sponsors face.

EMA has postponed formal adoption of the policy on publication of clinical trial data until its October 2, 2014 meeting

Although the pace of approvals for new orphan drugs have increased in the United States and Europe in recent years, patients are facing growing challenges accessing those drugs.

inVentiv Clinical Trial Recruitment Solutions and the Alliance for Clinical Research Excellence and Safety are partnering toward the development of a global system

Key to accelerating the discovery and development of new medical therapies is to improve the clinical research process.

Further discussion required on wording and practical arrangements

EFPIA criticized the intent of the French government to broadly enlarge the use of off-label drugs for economic reasons, even if there is an approved drug available.

The French government's intention to broadly enlarge the use of off-label drugs for economic reasons is wrong, according to a statement issued by EFPIA

he Lithuanian Ministry of Health and EFPIA, the European Federation of Pharmaceutical Industries and Associations announced a significant new Joint Working Agreement that paves the way for protecting future health and growth in Lithuanian.